Join Free For Buyer|Sign In

Professional Online Trade Platform for API, Preparation and Pharmaceutical Machinery and Equipment_EN-CPhI.cn

You are here:  Home >>  News >>  Market News >>  Avalon GloboCare, GE Healthcare to accelerate bioproduction of cellular medicines

Avalon GloboCare, GE Healthcare to accelerate bioproduction of cellular medicines

July 23, 2019 By biospectrumasia

Avalon GloboCare Corp., a leading clinical-stage global developer of cell-based technologies and therapeutics, has announced that they have established a strategic partnership with GE Healthcare. 

The partnership will accelerate Avalon’s standardization, automation and bio-production for clinical-grade Chimeric Antigen Receptor (CAR)-T cells and other immune-effector cells for cellular immunotherapy, as well as exosomes/extracellular vesicles (EV) based regenerative therapeutics. 

The combination of expertise sets the stage for Avalon to be the leader in cellular medicines with the ability to execute on the complete development lifecycle from innovation through bio-production to the delivery and management of treatment at hospitals for patients.  This infrastructure and depth of capabilities ensures the successful execution of the company’s ongoing clinical trials.

Under this partnership, both Avalon and GE Healthcare will strategically establish automated and standardized GMP cell production capabilities.  Avalon will be given access to GE Healthcare’s cell processing expertise and products in the form of FlexFactory Cell Therapy platform, FastTrak process development and training services, as well as extensive SOP and validation protocol library. 

Additionally, user training will be conducted both at GE Healthcare and on-site at Avalon’s Nanjing Epicon GMP facility with access to GE Healthcare’s expert bio-manufacturing resources.  In conjunction with Avalon’s extensive clinical network in China, this strategic partnership will empower Avalon to improve manufacturing throughput and efficiency, alleviate cost burden, and minimize variability in the automated and standardized bio-production process of clinical-grade cellular products (such as CAR-T, CAR-NK, and stem cell-derived exosomes/EV), therefore, accelerating the development of Avalon’s clinical and commercialization programs in cellular medicines.

Readers'Comments
Add a comment
Click here to Login or to Register for free. You will be taken back to your selected item after Login/Registration.
More>> MarketNews
More>> Editors’Picks
More>> TopStories
More>> HotTags
Follow Us
CPhI Online Trade Platform: Worldwide|English|中国站
Customer Service:  86-400 610 1188 (9: 00-18: 00, Mon-Fri)
About Us| Contact Us| Terms of Services| Privacy Policy| Intellectual Property Statement| Links | Site Map
Copyright 2006-20 Shanghai Sinoexpo Informa Markets International Exhibition Co. Ltd (All Rights Reserved). ICP 05034851-53
网页对话
live chat